secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001689548-25-000021
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis reports $470M cash, NDA plans for ulixacaltamide in 2025, and UCB option exercise for KCNT1
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities ~$470M at Dec 31, 2024; runway into 2028.
- Interim analysis of Essential3 Study 1 for ulixacaltamide in essential tremor expected Q1 2025; NDA filing planned for 2025.
- UCB exercised option to license KCNT1 small molecule; Praxis eligible for up to ~$100M milestones plus tiered royalties.
- RADIANT (vormatrigine) topline in H1 2025; POWER1 (vormatrigine) topline by year-end 2025.
- EMBOLD cohort 2 for relutrigine on track with NDA filing expected in 2026; third RPDD received for Dravet Syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/0001689548-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/prax-20250112.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer